Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythromycin Effect on Relugolix PK in Healthy Volunteers
NCT04714554Phase 1Completed
- Sponsor
- Myovant Sciences
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of relugolix in Uterine Fibroids (UF), endometriosis and prostate cancer (PCa) (2 arms), sponsored by Myovant Sciences. Primary endpoints: Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity and Maximum Plasma Concentration. Started Jan 2021; status: completed.
02
Drugs
relugolix
03
Conditions
Uterine Fibroids (UF)endometriosisprostate cancer (PCa)
Beyond the preview
Go deeper on NCT04714554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714554.